Skyhawk Therapeutics

Revolutionizing disease treatment by modifying RNA expression

Waltham, United States · Founded 2016 · $181.0M raised

Employees
11–50
Founded
2016
Business Model
B2B
Total Funding
$181.0M
Last Round
$133.0M Series BSep 2021
Rounds
3

About

Skyhawk Therapeutics is a clinical-stage biotechnology company founded in 2016 and headquartered in Waltham, Massachusetts. The company develops small molecule therapeutics that modify RNA expression via its proprietary SkySTAR platform, targeting diseases including multiple sclerosis, spinal muscular atrophy, ALS, Huntington's disease, and cancers. Skyhawk's founders co-developed Evrysdi (risdiplam), the first approved small molecule to modulate RNA splicing, for the treatment of Spinal Muscular Atrophy. The company has established pharma collaborations contributing upfront payments of over $550 million, including a strategic research collaboration with Vertex Pharmaceuticals announced in December 2020.

Summary

Skyhawk Therapeutics is a Biotech company based in Waltham, United States, founded in 2016. It has raised $181.0M in total across 3 rounds, most recently a $133.0M Series B round in Sep 2021. Investors include Alexandria Venture Investments and GreatPoint Ventures.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BSep 2021
$133.0M

Sign up to see all 3 rounds

Seed through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Skyhawk Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/skyhawk-therapeutics"><img src="https://indexed.vc/api/badge/company/skyhawk-therapeutics" alt="Skyhawk Therapeutics on Indexed.vc" width="260" height="76" /></a>